Published Date:2021-06-08 Original Link:https://www.onenessbio.com/en/news_detail46_3.htm No 1 Date of announcement 2021/06/08 Time of announcement 21:27:47 Subject An IND was submitted to US FDA for a phase II clinical trial of FB704A, an anti-IL6 mAb developed by Oneness, for treating severe COVID-19.      To which item it meets paragraph 10 Date of events 2021/06/08 Statement 1.Product:FB704A...Read More

Published Date:2021-06-03 Original Link:https://www.onenessbio.com/en/news_detail45_3.htm No 1 Date of announcement 2021/06/03 Time of announcement 18:48:46 Subject The Phase 3 international MRCT study results of the diabetic foot ulcer new drug, Fespixon have been accepted for oral presentation at the 57th EASD Annual Meeting      To which item it meets paragraph 12 Date of events 2021/06/03...Read More

Published Date:2021-06-01 Original Link:https://www.onenessbio.com/en/news_detail44_3.htm No 1 Date of announcement 2021/06/01 Time of announcement 19:10:51 Subject A Chinese patent titled “USE OF FLAVOIDS IN MANUFACTURING COMPOSITIONS FOR WOUND HEALING.” has been granted.      To which item it meets paragraph 53 Date of events 2021/06/01 Statement 1.Date of occurrence of the event:2021/06/01 2.Company name:ONENESS BIOTECH CO.,...Read More

Published Date:2021-05-21 Original Link:https://www.onenessbio.com/en/news_detail43_3.htm No 1 Date of announcement 2021/05/21 Time of announcement 16:04:07 Subject The annual shareholders’ meeting will be postponed in accordance with the instructions of FSC.      To which item it meets paragraph 53 Date of events 2021/05/21 Statement 1.Date of occurrence:2021/05/21 2.Due to “Measures for public companies to postpone shareholders’...Read More

Published Date:2021-05-14 Original Link:https://www.onenessbio.com/en/news_detail42_3.htm No 1 Date of announcement 2021/05/14 Time of announcement 18:52:44 Subject A Taiwan patent titled “Biomarkers for lung cancer stem cells” has been granted      To which item it meets paragraph 53 Date of events 2021/05/14 Statement 1.Date of occurrence of the event:2021/05/14 2.Company name:ONENESS BIOTECH CO., LTD. 3.Relationship to...Read More

Published Date:2021-05-11 Original Link:https://www.onenessbio.com/en/news_detail41_3.htm No 1 Date of announcement 2021/05/11 Time of announcement 21:15:12 Subject A Chinese patent titled ”Use of Plectranthus amboinicus extract in manufacturing compositions for anti-microbial effect”has been granted.      To which item it meets paragraph 53 Date of events 2021/05/11 Statement 1.Date of occurrence of the event:2021/05/11 2.Company name:ONENESS BIOTECH...Read More

Published Date:2021-05-06 Original Link:https://www.onenessbio.com/en/news_detail40_3.htm No 3 Date of announcement 2021/05/06 Time of announcement 19:48:22 Subject A Taiwan patent titled “Method for treating cancer using cd14 antagonists” has been granted.      To which item it meets paragraph 10 Date of events 2021/05/06 Statement 1.Date of occurrence of the event:2021/05/06 2.Company name:ONENESS BIOTECH CO., LTD. 3.Relationship...Read More

Published Date:2021-04-19 Original Link:https://www.onenessbio.com/en/news_detail38_3.htm No 2 Date of announcement 2021/04/19 Time of announcement 19:32:01 Subject Oneness received approval by TFDA on the phase 2 clinical trial application for FB704A, a fully-human anti-IL6 antibody new drug, in severe asthma.      To which item it meets paragraph 10 Date of events 2021/04/19 Statement 1.Product:FB704A 2.Mass production...Read More

Published Date:2021-04-12 Original Link:https://www.onenessbio.com/en/news_detail37_3.htm No 1 Date of announcement 2021/04/12 Time of announcement 20:52:15 Subject Oneness announces that Nanchou manufacturing site has been GMP and GDP certified by MOHW      To which item it meets paragraph 53 Date of events 2021/04/12 Statement 1.Date of occurrence of the event:2021/04/12 2.Company name:Oneness Biotech Co., Ltd. 3.Relationship...Read More

Published Date:2021-04-07 Original Link:https://www.onenessbio.com/en/news_detail36_3.htm No 1 Date of announcement 2021/04/07 Time of announcement 19:21:18 Subject Oneness has submitted the phase 2 clinical trial application for FB704A, a fully-human anti-IL6 antibody new drug, in severe asthma to TFDA via fast track.      To which item it meets paragraph 10 Date of events 2021/04/07 Statement 1.Product:FB704A...Read More